β2-アドレナゲン受容体シグナリングのダイナミックプロセスに関する構造的洞察
Aashish Manglik1, Tae Hun Kim2, Matthieu Masureel1
1Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA.
Cell
|May 19, 2015
まとめ
Gタンパク質結合受容体 (GPCRs) は,異なる形状を採用しています. アゴニストはベータ-2アドレネルゲン受容体 (β2AR) を部分的に活性化し,完全なシグナル伝達にはGタンパク質の相互作用が必要です.
科学分野:
- バイオケミストリー バイオケミストリー
- 構造生物学 構造生物学とは
- 薬理学 薬理学とは
背景:
- Gタンパク質結合受容体 (GPCR) は,信号伝達に関与する重要な細胞表面受容体である.
- GPCRの構成動態を理解することは,それらの規制メカニズムを解読する鍵です.
研究 の 目的:
- ベータ-2 アドレナリゲン受容体 (β2AR) の細胞質領域の構造的ダイナミクスを調査する.
- 信号伝達中に細胞外リガンドがGPCR構成をどのように調節するかを解明する.
主な方法:
- (19) F-フッ素核磁気共振 (NMR) スペクトロスコーピーを利用しました.
- タンパク質のダイナミクスを研究するために,二重電子-電子共振 (DEER) スペクトロスコーピーを用いた.
主要な成果:
- 無結合および逆アゴニスト結合β2ARは,2つの非活性構造体で存在します.
- アゴニストは活発な形状を促しますが,不活性,中間,活性状態が共存して異質性につながります.
- 活性構造の完全な活性化には,その後のGタンパク質の相互作用が必要である.
結論:
- GPCRsは,リガンド結合によって影響される複雑な構成の風景を示します.
- リガンド結合部位とGタンパク質結合インターフェースの間には,緩やかなアロステル結合が存在します.
- このメカニズムは,様々なGPCRの複雑なシグナル伝達行動を説明するかもしれない.
関連する概念動画
Sympathetic Signaling
3.5K
Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
3.5K
Adrenergic Receptors: β Subtype
4.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.6K
Adrenergic Receptors (Adrenoceptors): Classification
5.7K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
5.7K
Adrenergic Receptors: ɑ Subtype
3.3K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.3K
The Two-State Receptor Model
3.6K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
3.6K
Amplifying Signals via Enzymatic Cascade
19.6K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.6K


